Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Flaherty

Showing results (151-160 of 242) with videos related to

Pageof 25
Sort By:
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Scientific Reports|July 1, 2017
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
Scientific Reports|April 26, 2017
The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
American Journal of Respiratory Cell and Molecular Biology|December 12, 2013
Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis modelLynne A Murray, Huilan Zhang, Sameer R Oak, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
Pageof 25

Showing results (151-160 of 242) with videos related to

Sort By:
Pageof 25
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Scientific Reports|July 1, 2017
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
Scientific Reports|April 26, 2017
The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
American Journal of Respiratory Cell and Molecular Biology|December 12, 2013
Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis modelLynne A Murray, Huilan Zhang, Sameer R Oak, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
Pageof 25